HC Wainwright Issues Negative Estimate for Zynex Earnings

Zynex, Inc. (NASDAQ:ZYXI) – Stock analysts at HC Wainwright dropped their Q1 2025 earnings per share estimates for shares of Zynex in a research report issued on Wednesday, March 12th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings per share of ($0.20) for the quarter, down from their prior forecast of $0.07. HC Wainwright currently has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for Zynex’s current full-year earnings is $0.20 per share. HC Wainwright also issued estimates for Zynex’s Q2 2025 earnings at ($0.10) EPS, Q3 2025 earnings at ($0.07) EPS, Q4 2025 earnings at ($0.04) EPS and FY2025 earnings at ($0.40) EPS.

Zynex (NASDAQ:ZYXI) last issued its earnings results on Tuesday, March 11th. The company reported ($0.02) EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.11). Zynex had a return on equity of 13.05% and a net margin of 2.49%. The firm had revenue of $45.98 million for the quarter, compared to analysts’ expectations of $53.65 million. During the same period last year, the firm earned $0.04 earnings per share.

A number of other equities analysts have also recently weighed in on the company. Royal Bank of Canada cut Zynex from an “outperform” rating to a “sector perform” rating and lowered their price target for the stock from $11.00 to $5.50 in a report on Wednesday, March 12th. LADENBURG THALM/SH SH lowered shares of Zynex from a “buy” rating to a “neutral” rating in a research note on Wednesday, March 12th.

Zynex Trading Up 2.4 %

ZYXI opened at $2.97 on Monday. The business’s 50 day moving average price is $7.42 and its 200 day moving average price is $7.91. The company has a debt-to-equity ratio of 1.66, a quick ratio of 3.15 and a current ratio of 3.94. The stock has a market capitalization of $94.78 million, a PE ratio of 19.80 and a beta of 0.81. Zynex has a one year low of $2.77 and a one year high of $13.19.

Hedge Funds Weigh In On Zynex

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ZYXI. Hotchkis & Wiley Capital Management LLC boosted its holdings in Zynex by 24.7% in the third quarter. Hotchkis & Wiley Capital Management LLC now owns 746,380 shares of the company’s stock valued at $6,090,000 after purchasing an additional 147,770 shares during the period. GSA Capital Partners LLP raised its position in Zynex by 72.7% in the 3rd quarter. GSA Capital Partners LLP now owns 79,930 shares of the company’s stock valued at $652,000 after purchasing an additional 33,649 shares in the last quarter. Lido Advisors LLC purchased a new position in shares of Zynex in the 4th quarter valued at about $240,000. Geode Capital Management LLC grew its position in shares of Zynex by 6.7% during the third quarter. Geode Capital Management LLC now owns 425,509 shares of the company’s stock worth $3,473,000 after buying an additional 26,774 shares in the last quarter. Finally, KLP Kapitalforvaltning AS purchased a new stake in shares of Zynex during the fourth quarter worth approximately $211,000. Hedge funds and other institutional investors own 29.68% of the company’s stock.

Insider Activity

In related news, CFO Daniel J. Moorhead sold 10,000 shares of Zynex stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $7.68, for a total value of $76,800.00. Following the completion of the transaction, the chief financial officer now owns 19,738 shares in the company, valued at approximately $151,587.84. The trade was a 33.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Over the last ninety days, insiders sold 30,000 shares of company stock valued at $227,100. 52.13% of the stock is currently owned by corporate insiders.

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.